FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANIKA THERAPEUTICS, INC.
CENTRAL INDEX KEY:
STANDARD INDUSTRIAL CLASSIFICATION:
IRS NUMBER: 043145961
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K/A
SEC ACT:
SEC FILE NUMBER: 000-21326
FILM NUMBER
BUSINESS ADDRESS:
STREET 1: 236 WEST CUMMINGS PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: 7819326616
MAIL ADDRESS:
STREET 1: 236 WEST CUMMINGS PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
FORMER COMPANY:
FORMER CONFORMED NAME: ANIKA RESEARCH, INC.
DATE OF NAME CHANGE: 19970108
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------------------------
Form 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES AND EXCHANGE ACT OF 1934
May 28, 1998
-----------------
(Date of Report)
ANIKA THERAPEUTICS, INC.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 000-21326 04-3145961
------------------------ ------------ ----------
(State or Other Juris- (Commission (IRS Employer
diction of Incorporation) File No.) Identification No.)
236 West Cummings Park
Woburn, MA 01801
----------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: 781-932-6616
----------------------------------------------------------------
<PAGE>
ITEM 4. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT.
KPMG Peat Marwick LLP was previously the principal accountants for Anika
Therapeutics, Inc. Effective May 6, 1998 that firm's appointment as principal
accountants was terminated and Arthur Andersen LLP was engaged as principal
accountants. The decision to change accountants was unanimously approved by
the Board of Directors.
In connection with the audits of the balance sheets as of
December 31, 1997 and 1996 and the related statements of operations,
stockholders' equity and cash flows for the year ended December 31, 1997,
the four month transition year ended December 31, 1996 and the year ended
August 31, 1996 and the subsequent interim period through May 6, 1998,
there were no disagreements with KPMG Peat Marwick LLP on any matter of
accounting principles or practices, financial statement disclosure, or
auditing scope or procedures which disagreements if not resolved to their
satisfaction would have caused them to make reference in connection with
their opinion to the subject matter of the disagreement.
The audit reports of KPMG Peat Marwick LLP for the balance sheets
of Anika Therapeutics, Inc. as of December 31, 1997 and 1996 and the related
statements of operations, stockholders' equity and cash flows for the year
ended December 31, 1997, the four month transition year ended
December 31, 1996 and the year ended August 31, 1996 did not contain any
adverse opinion or disclaimer of opinion nor were they qualified or modified
as to uncertainty, audit scope, or accounting principles. A letter from
KPMG Peat Marwick LLP is attached as an exhibit.
During the registrant's year ended December 31, 1997, four month
transition year ended December 31, 1996, year ended August 31, 1996 and the
subsequent interim periods, Arthur Andersen LLP has not been engaged as an
independent accountant to audit either the registrant's financial statements
or the financial statements of any of its subsidiaries, nor has it been
consulted regarding the application of the registrant's accounting
principles, either completed or proposed, or the type of opinion that might
be rendered on the registrant's financial statements.
<PAGE>
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
<TABLE>
<CAPTION>
(c) Exhibits.
Exhibit No. Description
<S> <C>
16.1 Letter regarding Change in Certifying Accountants.
Letter dated May 6, 1998 from KPMG Peat Marwick LLP to
the Registrant. Filed herewith.
16.2 Letter regarding Change in Certifying Accountants.
Letter dated May 6, 1998 from KPMG Peat Marwick LLP to
the Securities & Exchange Commission. Filed herewith.
</TABLE>
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigend hereunto duly authorized.
ANIKA THERAPEUTICS, INC.
By: /s/ Sean Moran
----------------
Name: Sean Moran
Title: Chief Financial Officer
Date: May 28, 1998
<PAGE>
EXHIBIT 16.1
May 6, 1998
Mr. Sean Moran
Chief Financial Officer
Anika Therapeutics, Inc.
236 West Cummings Park
Woburn, MA 01801
Dear Mr. Moran:
This is to confirm that the client-auditor relationship between Anika
Therapeutics, Inc. and KPMG Peat Marwick, LLP has ceased.
Very truly yours,
/s/ KPMG Peat Marwick LLP
KPMG Peat Marwick LLP
cc: Chief Accountant
Securities and Exchange Commission
<PAGE>
EXHIBIT 16.2
May 6, 1998
Securities and Exchange Commission
Washington, DC 20549
Ladies and Gentlemen:
We were previously principal accountants for Anika Therapeutics, Inc. and,
under the date of February 18, 1998 we reported on the balance sheets of
Anika Therapeutics, Inc., as of December 31, 1997 and 1996, and the related
statements of operations, stockholders' equity and cash flows for the year
ended December 31, 1997, the four month transition year ended
December 31, 1996 and the year ended August 31, 1996. On May 6, 1998 our
appointment as principal accountants was terminated. We have read Anika
Therapeutics, Inc.'s statements included under Item 4 of its Form 8-K dated
May 8, 1998 and we agree with such statements except that we are not in a
position to agree or disagree with Anika Therapeutics, Inc. statement that
the appointment of Arthur Andersen LLP was unanimously approved by the board
of directors. We are also not in a position to agree or disagree with
Anika Therapeutics, Inc.'s statement that Arthur Andersen LLP was not
engaged regarding the application of accounting principles, either completed
or proposed, or the type of opinion that might be rendered on Anika
Therapeutics, Inc.'s financial statements.
Very truly yours,
/s/ KPMG Peat Markwick LLP
KPMG Peat Marwick LLP
cc: Mr. Sean Moran, CFO
Anika Therapeutics, Inc.
